Adjuvant treatments for resected pancreatic adenocarcinoma: A systematic review and network meta-analysis

The Lancet Oncology

Volumn 14, Issue 11, 2013, Pages 1095-1103

  Liao, Wei Chih ^a,d   Chien, Kuo Liong ^a,d   Lin, Yu Lin ^a,b   Wu, Ming Shiang ^a   Lin, Jaw Town ^c   Wang, Hsiu Po ^a   Tu, Yu Kang ^d  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GEMCITABINE;

ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CHEMORADIOTHERAPY; HUMAN; LEUKOPENIA; LYMPH NODE METASTASIS; META ANALYSIS; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; SYSTEMATIC REVIEW; THROMBOCYTOPENIA;

ADENOCARCINOMA; CHEMORADIOTHERAPY, ADJUVANT; HUMANS; META-ANALYSIS AS TOPIC; PANCREATIC NEOPLASMS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84884701341     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70388-7     Document Type: Article

References (35)

1. Siegel R, Naishadham D, Jemal A Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
2. Sener SF, Fremgen A, Menck HR, Winchester DP Pancreatic cancer: a report of treatment and survival trends for 100 313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 1999, 189:1-7.
3. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007, 297:267-277.
4. Twombly R Adjuvant chemoradiation for pancreatic cancer: few good data, much debate. J Natl Cancer Inst 2008, 100:1670-1671.
5. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004, 350:1200-1210.
6. Ueno H, Kosuge T, Matsuyama Y, et al. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer 2009, 101:908-915.
7. Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997, 15:2403-2413.
8. Abrams RA, Yeo CJ Combined modality adjuvant therapy for resected periampullary pancreatic and nonpancreatic adenocarcinoma: a review of studies and experience at The Johns Hopkins Hospital, 1991-2003. Surg Oncol Clin N Am 2004, 13:621-638.
9. Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 2008, 299:1019-1026.
10. Yeo CJ, Abrams RA, Grochow LB, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 1997, 225:621-633.
11. Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001, 358:1576-1585.
12. Smeenk HG, van Eijck CH, Hop WC, et al. Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891. Ann Surg 2007, 246:734-740.
13. Stocken DD, Buchler MW, Dervenis C, et al. Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer 2005, 92:1372-1381.
14. Ades AE, Sculpher M, Sutton A, et al. Bayesian methods for evidence synthesis in cost-effectiveness analysis. Pharmacoeconomics 2006, 24:1-19.
15. Sutton A, Ades AE, Cooper N, Abrams K Use of indirect and mixed treatment comparisons for technology assessment. Pharmacoeconomics 2008, 26:753-767.
16. Song F, Altman DG, Glenny AM, Deeks JJ Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003, 326:472-476.
17. Woods BS, Hawkins N, Scott DA Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: a tutorial. BMC Med Res Methodol 2010, 10:54-62.
18. Moher D, Liberati A, Tetzlaff J, Altman DG Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009, 339:b2535.
19. Higgins JP, Altman DG Assessing risk of bias in included studies. Cochrane handbook for systematic reviews of interventions: Cochrane book series 2008, 187-241. John Wiley & Sons, Chichester. J.P. Higgins, S. Green (Eds.).
20. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007, 8:16-31.
21. Sperti C, Pasquali C, Piccoli A, Pedrazzoli S Recurrence after resection for ductal adenocarcinoma of the pancreas. World J Surg 1997, 21:195-200.
22. Liao WC, Wang HP, Huang HY, et al. CXCR4 expression predicts early liver recurrence and poor survival after resection of pancreatic adenocarcinoma. Clin Transl Gastroenterol 2012, 13:e22-e32.
23. Dias S, Sutton AJ, Welton NJ, Ades AE NICE DSU technical support document 3: heterogeneity: subgroups, meta-regression, bias and bias-adjustment report by the decision support unit. September 2011 (last updated April 2012) (accessed Aug 12, 2013). http://www.nicedsu.org.uk/TSD3%20Heterogeneity.final%20report.08.05.12.pdf.
24. Brooks SP, Gelman A General methods for monitoring convergence of iterative simulations. J Comput Graph Stat 1998, 7:434-455.
25. Kalser MH, Ellenberg SS Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985, 120:899-903.
26. Regine WF, Winter KA, Abrams R, et al. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the US Intergroup/RTOG 9704 phase III trial. Ann Surg Oncol 2011, 18:1319-1326.
27. Neoptolemos JP, Stocken DD, Tudur Smith C, et al. Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials. Br J Cancer 2009, 100:246-250.
28. Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010, 304:1073-1081.
29. Roy R, Maraveyas A Chemoradiation in pancreatic adenocarcinoma: a literature review. Oncologist 2010, 15:259-269.
30. Hutchins LF, Unger JM, Crowley JJ, Coltman CA, Albain KS Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999, 341:2061-2067.
31. Talarico L, Chen G, Pazdur R Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol 2004, 22:4626-4631.
32. Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 2011, 29:3457-3465.
33. Dees EC, O'Reilly S, Goodman SN, et al. A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer. Cancer Invest 2000, 18:521-529.
34. Tuveson DA, Neoptolemos JP Understanding metastasis in pancreatic cancer: a call for new clinical approaches. Cell 2012, 148:21-23.
35. Pueyo G, Mesia R, Figueras A, et al. Cetuximab may inhibit tumor growth and angiogenesis induced by ionizing radiation: a preclinical rationale for maintenance treatment after radiotherapy. Oncologist 2010, 15:976-986.